http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-119314-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fee8212a58201e283609558ebe186494 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-227 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate | 2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07db455cb046d29c49d0f5623c5876ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4310fa2dad1c471678abf3c690b474d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f6ffef35e087d1206b25e4598a3307c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41ce9b6b1264d88b8b38d68098be68f1 |
| publicationDate | 2021-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-119314-A1 |
| titleOfInvention | b ADRENERGIC AGONIST AND ITS METHODS OF USE |
| abstract | Claim 1: A compound according to formula (1) or a pharmaceutically acceptable salt, characterized in that: A', B', W' and X' are each, independently, a nitrogen atom or a carbon atom; ring D' is a fused ring selected from 5-9 membered monocyclic or bicyclic benzo, heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and a 5 to 7 membered saturated or partially unsaturated carbocyclyl or heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R¹’ is independently hydrogen, halogen, RA, -CN, -NO₂, -SF₅, -O-, -OR’, -NR’₂, -SO₂R’, -C(O)R’, -C(O) NR'₂, -NR'C(O)R', -NR'CO₂R' or -CO₂R'; each RA is, independently, an optionally substituted group selected from C₁₋₆ aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a heteroaryl ring 5-6 membered having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two RA groups on the same carbon or optionally removed together with their intervening atoms to form a saturated or partially unsaturated carbocyclic or heterocyclic ring of 3 - 6 optionally substituted members having 1-3 heteroatoms, in addition to the carbon to which the two RA groups are attached, independently selected from nitrogen, oxygen and sulfur; each R' is, independently, hydrogen or an optionally substituted group selected from C₁₋₆ aliphatic, phenyl, a 3 to 8 membered monocyclic saturated or partially unsaturated carbocyclic ring, an 8 to 10 membered aromatic or partially unsaturated bicyclic carbocyclic ring, a 4 to 8 membered monocyclic saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, a 5 to 6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen , oxygen or sulfur, and an 8 to 10 membered partially unsaturated or heteroaromatic bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur, or: two R' groups on the same carbon or nitrogen are optionally removed together with its intervening atoms to form a saturated or partially unsaturated carbocyclic or heterocyclic ring. optionally substituted 4-10 membered radon having 1-3 heteroatoms, in addition to the carbon or nitrogen to which the two R' groups are attached, independently selected from nitrogen, oxygen and sulfur; m' is an integer from 0 to 3; R²' is selected from hydrogen, RA, -OR', or a compound from the group of formulas (2); L' is an optionally substituted C₁₋₅ alkylene; X¹', X³' and X⁴' are each, independently, a bivalent group selected from a covalent bond, -CR'₂-, -O- and -NR'-; X²' is a carbon atom or a nitrogen atom; Y' is O or S; R⁹' and R¹⁰' are each, independently, hydrogen or optionally substituted alkyl, or: R⁹' and R¹⁰' are cyclically linked and, together with X², form an optionally substituted 3- to 7-membered saturated carbocyclic ring; an optionally substituted 5 to 6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; an optionally substituted 3 to 7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; or an optionally substituted 7 to 12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; each R¹¹' is independently RA, halogen, -CN, -NO₂, -NR'₂ or -OR'; n' is an integer from 0 to 4; R¹²' is hydrogen, RA or -CN; each R¹³' is independently hydrogen, halogen, RA, -CN, -OR', or -NR'₂; and R⁷' and R⁸' are each, independently, hydrogen or optionally substituted aliphatic C₁₋₂. |
| priorityDate | 2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.